Status:
UNKNOWN
Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborating Sponsors:
Peking University First Hospital
China-Japan Friendship Hospital
Conditions:
Upper Tract Urinary Carcinoma
Muscle-invasive Bladder Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder cancer, especially chemotherapy combined with immunotherapy, however, available data of retrospective studies sho...
Eligibility Criteria
Inclusion
- bladder cancer of T2-4aN0M0
- upper tract urinary carcinoma of T1-3N0M0 and high grade
- ECOG 0-1
- good organ function
- no previous chemotherapy or immunotherapy
- Informed consent form signed
Exclusion
- unable to receive chemotherapy or surgery due to physical abnormalities
- previous cancer history
- active tuberculosis
- HIV
- autoimmune disease
- anticipating other clinical studies
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04099589
Start Date
October 1 2019
End Date
October 1 2022
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021